Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by dcoadtradeson Jul 27, 2018 11:18am
73 Views
Post# 28377179

RE:So much garbage on this board

RE:So much garbage on this boardAgreed! Great realistic, logical post.  
This board has slowly turning into a basher frenzy. 4 more months this could be like the ISOL board lol.
And the sad thing is I see a lot of green retail posters eating up the garbage and posting "I got scammed", "the sky is falling", "There's too many odd connections with Salzman group"  Yeah obvisiouly, that makes sense, do your own DD instead of just listening to a random!  I just dont think they knew what they were investing in. This is an early stage, no guarantees pharma stock. What gives this drug run a little percentage boost of making it to stage 3 and beyond is CBD(the future), and key word prevention.   
Dont beleive the hype kiddos, this one has a decent shot of making it. Groups of bashers dont waste their time on junk. This isnt the movies, shorters dont just short bad stocks, they play both sides of good ones. 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities